Homology Medicines, Inc. (NasdaqGS:FIXX) announced that it has completed a review of its business, and the Board of Directors has approved a plan to evaluate strategic alternatives to maximize shareholder value. Homology has retained TD Cowen as its strategic financial advisor. ?We are pleased with the initial data from the first dose level in our PKU gene editing trial, which support dose-escalation; however, given today?s tough financing conditions and the expected clinical development timeline for HMI-103, we believe the best path forward for our shareholders is to evaluate all strategic options for the Company and our pipeline,?

said Albert Seymour, Ph.D., President and Chief Executive Officer. ?Unfortunately, this decision impacts our dedicated employees, and I would like to extend my sincere gratitude to our affected colleagues who have been instrumental in building Homology?s platform and programs, and we are committed to supporting them as best as we can during this transition?. Strategic options may include but are not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, or other transactions.

There can be no assurance of completion of any particular course of action or a defined timeline for completion.